Loading clinical trials...
Loading clinical trials...
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
NCT07250646 · Secondary AML, Myelofibrosis
NCT06343805 · Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, and more
NCT07281781 · Myelofibrosis, Myelofibrosis; Anemia
NCT06781099 · Myelodysplastic Syndrome, Myelofibrosis
NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more
University of Michigan
Ann Arbor, Michigan
Royal Adelaide Hospital
Adelaide, South Australia
Universitatsklinikum Essen
Essen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions